Loading...
Powered By
34 items
2025-08-11
Santen Pharmaceutical Co., Ltd. provided consolidated earnings guidance for fiscal year ending March 31, 2026. For the year, the company expects Revenue of JPY 294,000 million, Operating Profit of JPY 44,000 million, Net profit for the year of JPY 33,500 million, Net Profit attributable to owners of company of JPY 34,000 million and basic earnings per share of JPY 102.66.
2025-08-01
Santen Pharmaceutical Co., Ltd., Board Meeting, May 13, 2025. Agenda: To consider Status of Share Buyback.
2025-07-23
Santen Pharmaceutical Co., Ltd., Q1 2026 Earnings Call, Aug 07, 2025
2025-07-01
From May 13, 2025 to June 30, 2025, the company has repurchased 4,378,900 shares, representing 1.28% for ¥7,168.96 million. With this, the company has completed the repurchase of 4,378,900 shares, representing 1.28% for ¥7,168.96 million under the buyback announced on May 13, 2025.
2025-06-06
Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
2025-05-17
Santen Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year core basis, the company expects revenue of JPY 294,000 million, core operating profit of JPY 54,000 million, net profit for the year of JPY 33,500 million and basic earnings per share of JPY 102.66. On an IFRS basis, operating profit is forecast to be ¥44.0 billion, down 6.1% from the previous fiscal year ended March 31, 2025 on an expected decrease in other expense and others. Net profit is forecast to be ¥33.5 billion, down 6.6% from the previous fiscal year ended March 31, 2025, and basic earnings per share is forecast to be ¥103, almost the same level as the previous fiscal year ended March 31, 2025, assuming the share buyback described on the previous section.
2025-05-17
Santen Pharmaceutical Co., Ltd. provided dividend guidance for the year ended March 31, 2026 of JPY 19.00 per share against JPY 19.00 per share paid a year ago.
2025-05-17
Santen Pharmaceutical Co., Ltd. announced dividend for the year ended March 31, 2025 of JPY 19.00 per share against JPY 17.00 per share a year ago. Start of Distribution of Dividends (Scheduled) is June 25, 2025. For the second quarter of year ending March 31, 2026, the company expects to pay the dividend of JPY 19 per share against JPY 17 per share a year ago.
2025-05-15
Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.
2025-05-15
The Board of Directors of Santen Pharmaceutical Co., Ltd. has authorized a buyback plan on May 13, 2025.
2025-05-14
Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.
2025-05-14
Santen Pharmaceutical Co., Ltd. expected to report Q1 2026 results on August 4, 2025. This event was calculated by S&P Global (Created on May 14, 2025).
2025-04-18
Santen Pharmaceutical Co., Ltd. - Interim Management Statement Call on May 21, 2025
2025-04-18
Santen Pharmaceutical Co., Ltd., Q4 2025 Earnings Call, May 13, 2025
2025-03-06
Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
2025-02-10
Santen Pharmaceutical Co., Ltd. announced that at its board meeting held on February 6, 2025, the board revised dividend guidance for the full year ending March 31, 2025. For the period, the company expected year-end dividend of JPY 19 per share compared to JPY 17 per share a year ago.
2025-02-06
Santen Pharmaceutical Co., Ltd. expected to report Fiscal Year 2025 results on May 13, 2025. This event was calculated by S&P Global (Created on April 17, 2025).
2025-01-23
Santen Pharmaceutical Co., Ltd. Presents at Veeva R&D and Quality Summit, Oct-31-2024 04:20 PM. Venue: Tokyo, Japan. Speakers: Mamoru Furuichi, Manager, Product Development System Management Team.
2025-01-09
Santen Pharmaceutical Co., Ltd., Q3 2025 Earnings Call, Feb 06, 2025
2024-12-19
Santen Pharmaceutical Co., Ltd. reported earnings results for the half year ended September 30, 2024. For the half year, the company reported sales was JPY 146,404 million. Basic earnings per share from continuing operations was JPY 52.88. Diluted earnings per share from continuing operations was JPY 52.74.
2024-12-13
The company closed its plan on December 12, 2024.
2024-12-13
From November 7, 2024 to December 12, 2024, the company has repurchased 5,000,000 shares, representing 1.43% for ¥8,490.43 million. With this, the company has completed the repurchase of 5,000,000 shares, representing 1.43% for ¥8,490.43 million under the buyback announced on November 7, 2024.
2024-12-03
Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
2024-11-11
Santen Pharmaceutical Co., Ltd. announced dividend of JPY 17.00 per share for the second quarter of the year ending March 31, 2025 compared to JPY 16.00 per share a year ago. Distribution of Dividends (Scheduled): November 29, 2024.
2024-11-08
Santen Pharmaceutical Co., Ltd., ¥ 19.0, Cash Dividend, Mar-28-2025
2024-11-07
Santen Pharmaceutical Co., Ltd. expected to report Q3 2025 results on February 7, 2025. This event was calculated by S&P Global (Created on November 7, 2024).
2024-11-07
From October 1, 2024 to November 6, 2024, the company has repurchased 2,806,800 shares, representing 0.79% for ¥5,005.61 million. With this, the company has completed the repurchase of 16,985,400 shares, representing 4.73% for ¥28,644.72 million under the buyback announced on May 9, 2024.
2024-11-07
The company closed its plan on November 6, 2024.
2024-11-07
Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.
2024-11-07
The Board of Directors of Santen Pharmaceutical Co., Ltd. has authorized a buyback plan on November 7, 2024.
2024-11-07
Santen Pharmaceutical Co., Ltd., Board Meeting, Nov 07, 2024. Agenda: To consider and resolve to cancel treasury shares.
2024-10-23
Santen Pharmaceutical Co., Ltd., Q2 2025 Earnings Call, Nov 07, 2024
2024-10-02
From July 1, 2024 to September 30, 2024, the company has repurchased 7,060,900 shares, representing 1.99% for ¥12,278.1 million. With this, the company has completed the repurchase of 14,178,600 shares, representing 3.95% for ¥23,639.11 million under the buyback announced on May 9, 2024.
2024-09-04
Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024
2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | |
|---|---|---|---|---|---|---|---|---|
Total Revenues | 293,970 | 300,004 | 301,905 | 302,563 | 304,347 | 301,965 | 302,084 | 295,928 |
Pretax Income Excl.Unusual Items | 43,883 | 49,816 | 46,472 | 44,486 | 45,304 | 44,722 | 77,919 | 75,943 |
Total Assets | 408,123 | 409,277 | 398,307 | 409,085 | 434,156 | 435,699 | 427,820 | 426,984 |
Total Liabilities | 127,909 | 124,096 | 115,096 | 120,831 | 128,219 | 130,329 | 129,836 | 120,529 |
Cash & Cash Equivalents | 84,578 | 92,997 | 77,851 | 84,441 | 89,744 | 94,582 | 82,030 | 64,728 |
Total Common Equity | 281,265 | 286,242 | 284,028 | 288,977 | 306,686 | 306,055 | 298,720 | 307,190 |
Book Value Per Share (BVPS) | 835.96 | 838.52 | 832.07 | 827.65 | 862.32 | 842.64 | 822.49 | 837.14 |
Net Change in Cash | -5,166 | -1,585 | -4,179 | 19,714 | 44,234 | 36,679 | 20,810 | -4,411 |
Capital Expenditure | -7,943 | -6,662 | -9,046 | -7,354 | -7,413 | -9,319 | -8,833 | -10,680 |
Santen Pharmaceutical revealed its financial results for the second quarter of 2025 on August 07, 2025, with revenues of 68.74B yen and net income of 5.88B yen, reflecting a 8.1% decline in revenue, along with a sharp drop of approximately 41.4% in EPS compared with the same quarter last year.
In addition, the EBITDA margin droped sharply from 23.9% in the corresponding quarter last year to 17.6%. A decrease in operating profitability may indicate a difficulty in sales or an increase in operating expenses, potentially harming the stock's future performance. Negatively, there is another notable figure. The quarterly free cash flow was 5.86B yen, which is a decrease of -5.7B yen over the same time last year. Even though the company's cash flow did not improve, the management returned a substantial amount of 14.46B yen to shareholders, of which 6.41B yen was paid as a dividend and 8.05B yen as a repurchase of Common Stock. The dividend yield for this stock is approximately 2.6%, and it trades at 17.2x times current year's earnings, which is higher than the sector average (P/E 9.6x).